Your browser doesn't support javascript.
loading
Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia.
de Vrij, Femke M; Bouwkamp, Christian G; Gunhanlar, Nilhan; Shpak, Guy; Lendemeijer, Bas; Baghdadi, Maarouf; Gopalakrishna, Shreekara; Ghazvini, Mehrnaz; Li, Tracy M; Quadri, Marialuisa; Olgiati, Simone; Breedveld, Guido J; Coesmans, Michiel; Mientjes, Edwin; de Wit, Ton; Verheijen, Frans W; Beverloo, H Berna; Cohen, Dan; Kok, Rob M; Bakker, P Roberto; Nijburg, Aviva; Spijker, Annet T; Haffmans, P M Judith; Hoencamp, Erik; Bergink, Veerle; Vorstman, Jacob A; Wu, Timothy; Olde Loohuis, Loes M; Amin, Najaf; Langen, Carolyn D; Hofman, Albert; Hoogendijk, Witte J; van Duijn, Cornelia M; Ikram, M Arfan; Vernooij, Meike W; Tiemeier, Henning; Uitterlinden, André G; Elgersma, Ype; Distel, Ben; Gribnau, Joost; White, Tonya; Bonifati, Vincenzo; Kushner, Steven A.
Afiliação
  • de Vrij FM; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Bouwkamp CG; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Gunhanlar N; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Shpak G; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Lendemeijer B; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Baghdadi M; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Gopalakrishna S; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Ghazvini M; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Li TM; Department of Developmental Biology, and Erasmus MC iPS Facility, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Quadri M; Department of Developmental Biology, and Erasmus MC iPS Facility, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Olgiati S; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Breedveld GJ; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Coesmans M; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Mientjes E; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • de Wit T; Delta Psychiatric Center, Poortugaal, The Netherlands.
  • Verheijen FW; Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Beverloo HB; ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Cohen D; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Kok RM; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Bakker PR; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Nijburg A; Mental Health Care Organization North-Holland North, Heerhugowaard, The Netherlands.
  • Spijker AT; Parnassia Psychiatric Institute, The Hague, The Netherlands.
  • Haffmans PMJ; Department of Psychiatry and Psychology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Hoencamp E; Psychiatric Center GGZ Centraal, Amersfoort, The Netherlands.
  • Bergink V; Parnassia Psychiatric Institute, The Hague, The Netherlands.
  • Vorstman JA; Faculty of Social and Behavioral Sciences Clinical, Health and Neuro Psychology, Department of Affective Disorders, PsyQ, Leiden University, Leiden, The Netherlands.
  • Wu T; Parnassia Psychiatric Institute, The Hague, The Netherlands.
  • Olde Loohuis LM; Institute of Psychology, Leiden University, Leiden, The Netherlands.
  • Amin N; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Hofman A; Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Hoogendijk WJ; Department of Psychiatry, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.
  • van Duijn CM; Program in Genetics and Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Ikram MA; Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
  • Vernooij MW; Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
  • Tiemeier H; Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Uitterlinden AG; Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Elgersma Y; Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Distel B; Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Gribnau J; Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • White T; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Bonifati V; Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Kushner SA; Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Mol Psychiatry ; 24(5): 757-771, 2019 05.
Article em En | MEDLINE | ID: mdl-29302076
Schizophrenia is highly heritable, yet its underlying pathophysiology remains largely unknown. Among the most well-replicated findings in neurobiological studies of schizophrenia are deficits in myelination and white matter integrity; however, direct etiological genetic and cellular evidence has thus far been lacking. Here, we implement a family-based approach for genetic discovery in schizophrenia combined with functional analysis using induced pluripotent stem cells (iPSCs). We observed familial segregation of two rare missense mutations in Chondroitin Sulfate Proteoglycan 4 (CSPG4) (c.391G > A [p.A131T], MAF 7.79 × 10-5 and c.2702T > G [p.V901G], MAF 2.51 × 10-3). The CSPG4A131T mutation was absent from the Swedish Schizophrenia Exome Sequencing Study (2536 cases, 2543 controls), while the CSPG4V901G mutation was nominally enriched in cases (11 cases vs. 3 controls, P = 0.026, OR 3.77, 95% CI 1.05-13.52). CSPG4/NG2 is a hallmark protein of oligodendrocyte progenitor cells (OPCs). iPSC-derived OPCs from CSPG4A131T mutation carriers exhibited abnormal post-translational processing (P = 0.029), subcellular localization of mutant NG2 (P = 0.007), as well as aberrant cellular morphology (P = 3.0 × 10-8), viability (P = 8.9 × 10-7), and myelination potential (P = 0.038). Moreover, transfection of healthy non-carrier sibling OPCs confirmed a pathogenic effect on cell survival of both the CSPG4A131T (P = 0.006) and CSPG4V901G (P = 3.4 × 10-4) mutations. Finally, in vivo diffusion tensor imaging of CSPG4A131T mutation carriers demonstrated a reduction of brain white matter integrity compared to unaffected sibling and matched general population controls (P = 2.2 × 10-5). Together, our findings provide a convergence of genetic and functional evidence to implicate OPC dysfunction as a candidate pathophysiological mechanism of familial schizophrenia.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteoglicanas de Sulfatos de Condroitina / Esquizofrenia / Células Precursoras de Oligodendrócitos / Proteínas de Membrana Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteoglicanas de Sulfatos de Condroitina / Esquizofrenia / Células Precursoras de Oligodendrócitos / Proteínas de Membrana Idioma: En Ano de publicação: 2019 Tipo de documento: Article